Sector practice head — Pharma & Biotech (USA) · CSO

Position overview

Gladwin International Leadership Advisors is representing a confidential organisation in Pharmaceuticals & Biotechnology on a senior CSO leadership mandate anchored in USA. The remit explicitly spans China, India, Africa.

This is a sector or practice-head mandate combining deep domain credibility with commercial ownership of a vertical P&L or global practice line.

The role suits an operator who treats integration, culture, and capital allocation as one system — not three separate programmes.

Context you will inherit

• Market & sector: USFDA and EMA compliance — finding quality and regulatory leaders who can restore and maintain approval status for facilities under import alert or warning letter, one of the sector's most acute leadership demands
• Geographic spine: Primary hub USA with explicit corridor responsibility across China, India, Africa.
• Organisation stage: Portfolio under review: non-core assets, JVs, and country footprints are actively questioned each planning cycle.
• Stakeholders: Stakeholders span board or regional executive committee, global functional heads, JV partners, and strategic account buyers.
• Secondary lens: CDMO scale-up — as global pharma companies diversify manufacturing into India, building world-class CDMO leadership with both technical excellence and customer relationship management

The mandate (12–24 month arc)

1. Advantage diagnosis: Separate structural advantage from cyclical tailwinds — be honest in board conversations.
2. Capability building: Decide what must be owned vs. partnered — avoid strategy that assumes impossible skills overnight.
3. War gaming: Regular exercises on competitor responses to our major moves.
4. Capital markets story: Align external narrative with internal strategy choices — no gap for activists to exploit.
5. Regulatory foresight: Early warning on rule changes that reshape economics of the sector.
6. Integration thesis: On deals, clarity on sources of value — revenue, cost, capability — with named owners.

Responsibilities (representative)

• Facilitate corporate strategy process — options, choices, and capital implications.
• Run strategic initiative PMO across the enterprise or region.
• Build M&A theme development and early diligences with corp dev.
• Deliver competitive and market intelligence to the executive committee.
• Support board strategy discussions with crisp materials and scenarios.

Leadership profile

• Communication: Executive presence in English; additional languages valued where market-relevant.
• Judgment: High signal-to-noise under pressure; ethical clarity; willingness to halt initiatives that break risk appetite.
• Strategy craft: Experience framing corporate choices with analytical rigour and executive alignment.
• Education: Strong undergraduate grounding; MBA / advanced degree / professional qualification common at this level.
• Geographic muscle: Comfort operating from USA with regular engagement across China, India.

Team & culture

The organisation runs hot — ambitious targets and thin buffers. You need to channel energy into sustainable rhythms: predictable planning, honest risk surfacing, and recovery time for teams after major pushes.

Success measures (examples)

• Financial: Revenue and margin vs. plan; cash conversion; capital efficiency.
• Strategic: Share in priority segments; customer retention in anchor accounts; milestone delivery on transformation.
• People: Engagement trends; regrettable attrition in critical roles; diversity of succession slate.
• Risk: Audit and regulatory outcomes; conduct events; operational resilience metrics.

First 90 days (orientation arc)

• Days 1–30: Shadow key customer journeys or operations — paper over slides where reality diverges.
• Days 30–60: Cut or pause low-value projects freeing capacity for strategic work.
• Days 60–90: Publish first integrated forecast or plan under your ownership — even if directional.
• Build trust with risk, legal, and audit through transparency — surprises erode licence to move fast.
• Pick one cultural signal (e.g. meeting hygiene, promotion criteria) and model it relentlessly.

Stakeholder map (illustrative)

• Internal: Matrix of global product houses and local P&L; tension is normal — your role is to broker trade-offs with data.
• External: Customers who influence reference deals; government or industry bodies in regulated sectors.
• Capital providers: Banks, sponsors, or minority investors — each needs a slightly different narrative on risk.

Travel & mobility

Role requires face-to-face presence in the primary hub with regular regional travel; remote-only not viable.

Compensation

Competitive CSO compensation for Pharmaceuticals & Biotechnology leadership: cash, incentive, benefits, and potential equity or carry (case-dependent). Discussed with finalists only.

Application status

This mandate is no longer accepting new applications. The search progressed through Q4 2025 and closed for submissions in February 2026. We retain this posting for transparency on the type of leadership work we carry in Pharmaceuticals & Biotechnology and USA. For similar active mandates, browse open roles or submit a general profile through executive search inquiry.

Reference: pharmaceuticals-biotech · CSO · USA · Gladwin International Leadership Advisors